Insmed (INSM) Misses Q1 EPS by 1c, Revenues Miss
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/15/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
- BOJ eyeing September rate hike, faster pace of tightening, sources say
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- SanDisk upgraded at JPMorgan after investor day; shares climb
- Micron: New Street upgrades to buy, says memory is no longer a cyclical story
Insmed Reports First Quarter 2021 Financial Results and Provides Business Update
May 6, 2021 7:30 AM EDTBRIDGEWATER, N.J., May 6, 2021 /PRNewswire/ --Â Insmed Incorporated (Nasdaq: INSM), a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases, today reported financial results for the first quarter ended March 31, 2021 and provided a business update. Â
"Insmed is off to a strong start in 2021, with important advancements across each of our three programs and our earlier-stage research activities, as well as meaningful progress in the buildout of our global organization," commented Will Lewis, Chair and Chief Executive Officer of... More
